CompletedPhase 4

Trial to Compare Two Strains of BCG

Guinea-Bissau16,390 participantsStarted 2020-05-04

Plain-language summary

The trial will be a two-year outcome assessor-blinded RCT at the maternity ward of hospital Simão Mendes (HNSM) in urban Bissau, Guinea-Bissau to compare BCG-Japan versus BCG-Russia 1:1 in 15,000 infants with respect to mortality, morbidity and case-fatality rate during hospital admission. The trial will also examine the association between BCG strains and BCG skin reaction characteristics by six weeks (data collected by telephone) and at two and six months (data collected at home-visits to a subgroup of the cohort). As a secondary aim, this large study will be used to further evaluate the role of maternal BCG immune priming for overall health, since there are indications that maternal BCG scarring enhances the non-specific effects of BCG.

Who can participate

Age range0 Days – 42 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy infants present at the HNSM maternity ward on the day of discharge or procuring vaccination at the ward. Exclusion Criteria: * Infants older than 6 weeks (\>42 days) of age * Infants that have already received either BCG or oral polio vaccine (OPV) * Infants that are moribund due to gross malformation or acute illness (about to die or be transferred to the pediatric ward according to the local health physician assessment; the latter children may be recruited when they are discharged from the pediatric ward or the neonatal intensive care unit).

What they're measuring

Rate of all-cause mortality overall and stratified by maternal BCG scar status and sex

Timeframe: Six weeks of age

Trial details

NCT IDNCT04383925

SponsorBandim Health Project

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-10-30

View on ClinicalTrials.gov More Death, Infant trials